News

95% of drug names elude doctors

Posted 29 July 2025 AM

A survey of neurologists used open-ended questions to capture unaided, top-of-mind recall for both approved and pipeline neurology drugs - and found that no single drug had greater than five per cent mindshare.

The neurology therapeutic landscape is one of the most intensely competitive, with hundreds of drugs vying for the attention of prescribers. This creates a significant challenge for pharmaceutical marketers trying to break through the noise to attract a neurologist's attention.

To see the whole article, please login